For Elevance Health and other big insurers, 2024 devolved into something of an annus horribilis over the year’s final weeks.

Elevance Health says its acquisition of Verily’s Granular Insurance is designed to bolster its offerings to self-funded ...

GreensKeeper Asset Management, an investment management company, released its fourth quarter investor letter. A copy of the ...

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target is $463.00. Whit Mayo has given his Buy rating due ...

Elevance Health shares fell 21% in 2024 due to weak fundamental performance, with revenue growing low-single-digits and flat earnings per share. The company is expanding its non-insurance ...

Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.

The board of Elevance Health, Inc. (NYSE:ELV) has announced that it will be paying its dividend of $1.71 on the 25th of March, an increased payment from last year's comparable dividend.

Elevance Health released fourth-quarter earnings that topped analyst expectations, sending its stock slightly higher in trading Thursday. Shares of Elevance surged in pre-market trading but have ...

Shares of Elevance Health Inc. ELV slid 1.24% to $391.22 Tuesday, on what proved to be an all-around positive trading session ...